Thioredoxin Systems AB is developing an innovative antibiotic regimen for complicated urinary tract infections caused by antibiotic-resistant bacteria. The technology is based on a novel mechanism of action that targets the bacterial antioxidant redox systems, thus promising to become an efficient treatment principle for many types of bacterial infections. EbsArgent™ is aiding medical professionals in the fight against antibiotic-resistant bacteria.
